MaxCyte Minutes Newsletter – Q3 2022

CRISPR Electroporation of T Cells Improves Treatment in Patients with Refractory Cancer

At MaxCyte®, we know that cells are precious. Especially when they are the key to novel treatments for patients in need. In this issue of the MaxCyte Minutes newsletter, we share some featured news, events, and technical content to show how we can help you with your next cell engineering project and expedite your research from concept to clinic and commercialization.



MaxCyte to support LG Chem CAR T programs

MaxCyte is thrilled to announce that we are partnering with LG Chem to support their CAR T programs for solid tumors. This partnership represents our first strategic platform license (SPL) with a South Korean company and broadens our reach into Asia. This collaboration enables us to provide advanced technologies that support the clinical and commercial development of engineered cell therapies that can treat cancer patients across the globe.

View More News image

Exploring Flow Electroporation® for Cell Engineering

Our Chief Scientific Officer, Dr. Cenk Sumen, recently spoke with Technology Networks about the numerous applications of cell engineering and how Flow Electroporation® technology can support cell engineering from small- to large-scale.

View More


Upcoming Webinar. Beyond affinity: antibody discovery, optimization, and developability screening from mammalian display libraries

Join us for a Lab roots Webinar and learn about detecting and avoiding antibodies with problematic developability profiles during early discovery. You can also find out about IONTAS’ novel technology for displaying antibodies on the surface of mammalian cells for antibody screening.

Date: Wednesday, October 19, 2022
Time:: 6:00am (PDT), 8:00am (EDT), 9:00am (CEST) REGISTER NOW cell-therapy-labroot

Featured Presentation: Which industry partner should I collaborate with? A scientists’ journey to implementing an innovative technology

At this year’s ASGCT (American Society of Gene and Cell Therapy) annual meeting, we were honored to have two of our clients, Dr. Jonathan Yen and Dr. Alicja Copik, present. They discussed how MaxCyte helped them unlock the full potential of their research by solving development and commercialization challenges.


Poster: In Vitro Characterization of CD19 CAR T Cells Derived

We also presented a poster at ASGCT! Here, MaxCyte electroporation was used to engineer T cells with mRNA. CAR T cells efficiently targeted and killed CD19-expressing cancer cells. If you missed the poster presentation, it’s available to download on our website.




Transient Protein Expression Will Revolutionize Bioproduction

Our Chief Scientific Officer, Dr. Cenk Sumen, recently contributed to a Genetic Engineering & Biotechnology News article offering insights into transient protein expression and its ability to transform bioproduction.




Rick Urbanski, Manufacturing Engineer

For this issue, we spent time with Rick Urbanski, from the Manufacturing Engineering team at MaxCyte. He designs and builds tooling to support manufacturing operations throughout the MaxCyte product portfolio. Let’s meet Rick!



emily-logo@2x September 17, 2022; 6:00 pm – 10:00 pm
Valley Forge Casino Resort King of Prussia, PA

Emily Whitehead Foundation – Believe Ball

VIEW ALL EVENTS BioProcess-International September 27 – September 30
Boston, MA

Biotech Week Boston

Leave a Comment